Zhejiang CONBA Pharmaceutical Co.,Ltd.

SHSE:600572 Stock Report

Market Cap: CN¥10.7b

Zhejiang CONBA PharmaceuticalLtd Past Earnings Performance

Past criteria checks 2/6

Zhejiang CONBA PharmaceuticalLtd has been growing earnings at an average annual rate of 23.4%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 0.6% per year. Zhejiang CONBA PharmaceuticalLtd's return on equity is 7.8%, and it has net margins of 8.1%.

Key information

23.4%

Earnings growth rate

23.4%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-0.6%
Return on equity7.8%
Net Margin8.1%
Next Earnings Update24 Aug 2024

Recent past performance updates

Recent updates

Here's Why Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Can Manage Its Debt Responsibly

May 21
Here's Why Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Can Manage Its Debt Responsibly

Revenue & Expenses Breakdown

How Zhejiang CONBA PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:600572 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 246,4265232,590314
31 Dec 236,7335922,833298
30 Sep 236,6967522,869217
30 Jun 236,6846622,905194
31 Mar 236,4305392,803194
31 Dec 226,0003582,582196
30 Sep 226,1412,0272,690207
30 Jun 226,5301,9842,825214
31 Mar 226,6782,0732,945210
31 Dec 216,5682,0173,001202
30 Sep 216,2821292,974196
30 Jun 215,8342152,907190
31 Mar 215,8213192,887184
31 Dec 205,9094532,979185
30 Sep 205,918-2763,062182
30 Jun 206,313-2523,335171
31 Mar 206,707-3423,753182
31 Dec 196,768-3463,844183
30 Sep 196,8555153,985201
30 Jun 196,9786524,025202
31 Mar 196,9757263,945191
31 Dec 187,0188153,954185
30 Sep 187,0678793,896167
30 Jun 186,6448803,589225
31 Mar 185,9797903,163185
31 Dec 175,2947112,655151
30 Sep 175,2665982,39696
30 Jun 175,3115192,2100
31 Mar 175,6404772,1120
31 Dec 166,0204412,1000
30 Sep 166,0922751,9830
30 Jun 166,1413081,9520
31 Mar 165,8824681,8970
31 Dec 155,3024401,8570
30 Sep 154,7587701,8990
30 Jun 154,1147041,8450
31 Mar 153,7465391,8100
31 Dec 143,5825521,7600
30 Sep 143,3985091,6440
30 Jun 143,2124991,6070
31 Mar 142,9854511,5370
31 Dec 132,9244171,5080
30 Sep 132,8244071,4770

Quality Earnings: 600572 has high quality earnings.

Growing Profit Margin: 600572's current net profit margins (8.1%) are lower than last year (8.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 600572's earnings have grown significantly by 23.4% per year over the past 5 years.

Accelerating Growth: 600572's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 600572 had negative earnings growth (-2.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).


Return on Equity

High ROE: 600572's Return on Equity (7.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.